CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia.
- Resource Type
- Article
- Authors
- Li, Qiaoqiao; Liang, Chunyan; Xu, Xintong; Zhang, Congli; Cao, Weijie; Wang, Meng; Jiang, Zhongxing; Xing, Haizhou; Yu, Jifeng
- Source
- Leukemia & Lymphoma. Sep2022, Vol. 63 Issue 9, p2136-2148. 13p.
- Subject
- *ACUTE myeloid leukemia
*HEMATOPOIETIC stem cell transplantation
*REGULATORY T cells
*KILLER cells
*CHIMERIC antigen receptors
- Language
- ISSN
- 1042-8194
The physiological function and prognostic significance of C-type lectin domain family 12 member A (CLEC12A) in acute myeloid leukemia (AML) patients are unclear. CLEC12A transcriptional expression in a variety of tumors from several public databases was collected and compared. We found that CLEC12A was highly expressed in AML cell lines and in tissues from AML patients and a higher CLEC12A expression in leukemia stem cells. CLEC12A low expression was associated with poor prognosis in the chemotherapy-only group and high CLEC12A expression may benefit from autologous or allogeneic hematopoietic stem cell transplantation (HSCT). CLEC12A expression was positively correlated with infiltrating levels of type 2 macrophages and monocytes and negatively associated with NK cells and regulatory T cells in AML. CLEC12A high was positively associated with immune checkpoint genes as well as macrophage associated genes. CLEC12A is an ideal chimeric antigen receptor T-cell (CAR-T) therapy target for AML and its expression level was closely linked to treatment response and patients' survival outcome. CLEC12A plays an important immunomodulatory role in AML. [ABSTRACT FROM AUTHOR]